Research Library › Peptide Fragments
PE-22-28 is a synthetic seven-amino-acid peptide corresponding to a shortened fragment of spadin, a natural peptide cleaved from the protein sortilin. It was first described in 2017 by Jean Mazella, Marc Borsotto and Catherine Heurteaux’s laboratory at France’s CNRS in Sophia Antipolis, and was designed to inhibit the TREK-1 potassium channel. It has been studied only in cells and mice, has never entered a human clinical trial, and is not FDA-approved.
Key facts
| Type | Synthetic seven-amino-acid peptide (heptapeptide) |
|---|---|
| Derived from | Spadin, a 17-amino-acid peptide released from the sortilin propeptide |
| First described | 2017, Frontiers in Pharmacology |
| Developed by | Mazella, Borsotto and Heurteaux laboratory, CNRS, Sophia Antipolis, France |
| Designed target | TREK-1 (K2P2.1) two-pore-domain potassium channel |
| Research stage | Cell and mouse studies only; no human trials identified |
| Regulatory status (Oct 2026) | Not FDA-approved; not evaluated by FDA's compounding advisory committee |
Who developed it
PE-22-28 comes from the laboratory of Jean Mazella, Marc Borsotto and Catherine Heurteaux at the Institute of Molecular and Cellular Pharmacology of France’s national research agency, CNRS, in Sophia Antipolis near Nice [1][2]. The same group had earlier discovered its parent peptide, spadin, and patented it in 2007 [1][3].
What it was designed to target
The design target is TREK-1, a two-pore-domain potassium channel that helps set the resting electrical state of neurons. Mice lacking TREK-1 had drawn attention from researchers studying mood-related neurobiology, which prompted the search for molecules that could block the channel [1].
The parent peptide, spadin, is a 17-amino-acid sequence released when the protein sortilin is processed. In 2010 the CNRS team reported that spadin binds and inhibits TREK-1 [1]. Spadin itself is broken down in the bloodstream, so the team analyzed the smaller fragments it generates. One seven-residue fragment, corresponding to positions 22–28 of the sortilin propeptide and named PE-22-28, inhibited TREK-1 more strongly than spadin in laboratory assays and showed longer stability in mice, with activity reported for up to 23 hours compared with about 7 hours for spadin [2].
Preclinical studies examined the peptide in the hippocampus and in the dorsal raphe nucleus, a brainstem region containing serotonin-producing neurons [1][2].
The 2017 study compared several shortened spadin analogs side by side, and PE-22-28 was selected from that series for further characterization [2].
Why it was created
Spadin and PE-22-28 arose from a research program on depression. The team’s stated interest was in a mechanism that might act faster than existing drug classes, whose onset typically takes several weeks [1]. A French government-funded project, run with the drug-delivery company MedinCell, was set up to carry out safety studies that could support a first human trial [4]. No human trial of PE-22-28 has been identified as of October 2026.
Research timeline
- 2007: Priority date of the CNRS patent covering spadin [3].
- 2010: Spadin described in PLOS Biology as a sortilin-derived TREK-1 blocker [1].
- 2013: French ANR project MEDINCOD launched with MedinCell [4].
- 2017: PE-22-28 and other shortened spadin analogs first described [2].
Regulatory status as of October 2026
As of 22 Oct 2026, PE-22-28 is not FDA-approved and has not been approved by any regulator. Published research consists of cell and mouse studies only [2]. It was not among the peptides evaluated by the FDA’s Pharmacy Compounding Advisory Committee in 2026.
Chemical suppliers distribute PE-22-28 labeled for research use only [5]. In 2026 the FDA issued warning letters to peptide vendors, making clear that a research-use-only label does not protect products that are marketed for human use [6].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who developed PE-22-28?
PE-22-28 was developed by the laboratory of Jean Mazella, Marc Borsotto and Catherine Heurteaux at CNRS in Sophia Antipolis, France, and first described in 2017.
What is PE-22-28 derived from?
It is a seven-amino-acid fragment of spadin, a 17-amino-acid peptide released from the protein sortilin. The name refers to its position, residues 22–28, in the sortilin propeptide.
Is PE-22-28 FDA approved?
No. As of 22 Oct 2026 PE-22-28 is not approved by the FDA or any other regulator, and no human clinical trial has been identified.
What does PE-22-28 target?
It was designed to inhibit TREK-1, a two-pore-domain potassium channel found in neurons. This interaction has been characterized in cells and mice.
Is PE-22-28 the same as spadin?
No. Spadin is the 17-amino-acid parent peptide described in 2010; PE-22-28 is a seven-amino-acid fragment of it reported in 2017.
Sources
- Mazella J et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLOS Biol. 2010;8(4):e1000355. Link
- Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity. Front Pharmacol. 2017;8:643. doi:10.3389/fphar.2017.00643 Link
- Mazella J, Petrault O, Borsotto M, Heurteaux C, Widmann C. US Patent 8,252,748 B2 (priority 21 Dec 2007). Link
- Agence Nationale de la Recherche. Project ANR-13-RPIB-0002, MEDINCOD. Link
- Cayman Chemical. Product insert, PE 22-28 (acetate), item 39986 (labeled for research only). Link
- Kundi A, Cowley EM, Golden S, Billan N (ArentFox Schiff). RUO-ined: five peptide vendors learn that "research use only" is not a legal strategy. 18 Sep 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
